Skip to content

Meryem Grabski

7 papers in the library · 257 citations · publishing 2020-2026

Papers

Sort Most recent Most cited

The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial

Addiction February 16, 2026 Cassie Bloy, Ananya Sarma, Bethan Marsh et al. 1 citation

People with alcohol use disorder experience alterations in consciousness from 0.8 mg/kg intravenous ketamine administration. Ketamine's effects appear to be broadly consistent across three repeated infusions. Ketamine-related reductions in alcohol consumption do not appear to be mediated by the acute psychoactive effects of ketamine.

Three-day blues after ecstasy/MDMA use: Evidence from a longitudinal and daily analysis in the European nightlife scene.

Drug and Alcohol Dependence September 12, 2025 Matthijs Blankers, Ruben Van Beek, Desirée Spronk et al. 1 citation

There is a lack of understanding of the nature of the post-acute affective response in the days after ecstasy/3,4-Methylenedioxymethamphetamine (MDMA) use and whether this is associated with ecstasy/MDMA use or circumstantial factors. In the three days following ecstasy/MDMA use, we evaluated whether a drop in mental well-being is observed and can be related to ecstasy use. Data for this study...

Polydrug Use Typologies of Regular Ecstasy Users Visiting Electronic Dance Music Events: A Latent Class Analysis.

European Addiction Research 2024 Ruben Johannes Jacob Van Beek, Matthijs Blankers, Marloes Kleinjan et al. 3 citations

Polydrug use patterns among young adults using ecstasy vary, as well as their willingness to change them. Polydrug use patterns are likely associated with different adverse health outcomes. It is unknown whether polydrug use patterns of young adults who use ecstasy are similar in different countries. This study aims to identify and compare polydrug use patterns and willingness to change them of...

Substance Use and Attendance Motives of Electronic Dance Music (EDM) Event Attendees: A Survey Study

International Journal of Environmental Research and Public Health January 19, 2023 Koen Ponnet, Bert Hauspie, Nicky Dirkx et al. 21 citations

EDM event attendees are a high-risk population for substance use and associated adverse effects. The aim of this study was to examine substance use at EDM events, focusing on associations between attendance motives and substance use. Sociodemographic characteristics, event specifics, past-year use, and attendance motives were assessed through an online survey. Participants were 1345 Belgian EDM...

Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder

American Journal of Psychiatry January 11, 2022 Meryem Grabski, Amy Mcandrew, Will Lawn et al. 169 citations

OBJECTIVE: Early evidence suggests that ketamine may be an effective treatment to sustain abstinence from alcohol. The authors investigated the safety and efficacy of ketamine compared with placebo in increasing abstinence in patients with alcohol use disorder. An additional aim was to pilot ketamine combined with mindfulness-based relapse prevention therapy compared with ketamine and alcohol...

"This Is Something That Changed My Life": A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders.

Frontiers in Psychiatry 2021 Özden Merve Mollaahmetoğlu, Johanna Keeler, Katherine J Ashbullby et al. 62 citations

Background: The therapeutic benefits of ketamine have been demonstrated for a variety of psychiatric disorders. However, the role of ketamine induced psychoactive experiences in mediating the therapeutic effects is unclear. Despite the growing quantitative research on the efficacy of ketamine treatment, very few studies examined participant experiences of ketamine infusions in a treatment...

Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review.

Behavioural Brain Research August 17, 2020 Meryem Grabski, Anna Borissova, Beth Marsh et al.

Esketamine was recently licensed by the US Food and Drug Administration (FDA) and European Drug Agency (EDA) for use in treatment resistant depression (TRD), and further research indicates ketamine as a possible treatment in other mental health conditions. While the underlying mechanisms remain unclear, it has been hypothesised that ketamine's acute psychoactive effects may be associated with...